Status:
COMPLETED
Evaluation of Silver Nanoparticles for the Prevention of COVID-19
Lead Sponsor:
Cluster de Bioeconomia de Baja California, A.C
Collaborating Sponsors:
Bionag SAPI de CV
General Hospital Tijuana
Conditions:
Coronavirus Disease 2019 (COVID-19)
Eligibility:
All Genders
20-73 years
Phase:
NA
Brief Summary
In this research, silver nanoparticles (AgNPs) were tested in vitro and shown to have an inhibitory effect on SARS-CoV-2 infection in cultured cells. Subsequently, the investigators assessed the effec...
Detailed Description
SARS-CoV-2 infection in hospital areas is of a particular concern, since the close interaction between health care personnel and patients diagnosed with COVID-19, which allows virus to be easily sprea...
Eligibility Criteria
Inclusion
- Men and women health workers in the General Tijuana Hospital, Mexico who works in high-risk areas with direct contact with patients infected and diagnosed with COVID-19.
Exclusion
- persons with history of hypersensitivity to silver (rashes and other contraindications),
- a history of SARS-CoV-2 infection in the three months prior to the start of the study, any respiratory distress,
- and refusal to sign the informed consent.
Key Trial Info
Start Date :
April 24 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 29 2020
Estimated Enrollment :
231 Patients enrolled
Trial Details
Trial ID
NCT04894409
Start Date
April 24 2020
End Date
September 29 2020
Last Update
May 20 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tijuana General Hospital
Tijuana, Estado de Baja California, Mexico, 22310